

COMMENTS:	FASTING:YE
	111011110.112

			Cardio IO	Q®				
	Cu	rrent	Risk	Reference In	terval		Hist	orical
Test Name	Resul	t & Risk	Optimal	Moderate	High	Units	Result	& Risk
	Optimal	Non-Optimal	optimu	moderate			04/21/2021	03/11/2021
LIPID PANEL								
CHOLESTEROL, TOTAL		329	<200	N/A	>=200	mg/dL	222	269
HDL CHOLESTEROL	58		>=40	N/A	<40	mg/dL	52	55
TRIGLYCERIDES	63		<150	150-199	>=200	mg/dL	54	52
LDL-CHOLESTEROL		255	<100	100-129	>129	mg/dL	155	200
						(calc)		
CHOL/HDLC RATIO		5.7	<=3.5	3.6-5.0	>5.0	calc	4.3	4.9
NON-HDL CHOLESTEROL		271	<130	130-189	>=190	mg/dL	170	214
						(calc)		
LIPOPROTEIN FRACTION	ATION, ION	MOBILITY		1				
LDL PARTICLE NUMBER		2255	<1138	1138-1409	>1409	nmol/L	1110	1837
LDL SMALL		293	<142	142-219	>219	nmol/L	99	181
LDL MEDIUM		638	<215	215-301	>301	nmol/L	240	447
HDL LARGE		6150	>6729	6729-5353	<5353	nmol/L	4294	5806
LDL PATTERN	A		A	N/A	В	Pattern	A	A
LDL PEAK SIZE		220.5	>222.9	222.9-217.4	<217.4	Angstrom	223.0	221.1
APOLIPOPROTEINS								
APOLIPOPROTEIN B		161	<90	90-119	>=120	mg/dL	104	121
LIPOPROTEIN (a)	10		<75	75-125	>125	nmol/L	12	<10

For details on reference ranges please refer to the reference range/comment section of the report.

CLIENT SERVICES: 866.697.8378

SPECIMEN:





Patient Information	Specimen Information	Client Information

4myheart Diet & Exercise Coaching Program: Need help achieving and maintaining an optimal weight? Managing stress? Trying to improve physical fitness levels? The 4myheart program provides support and personalized lifestyle guidance to help improve heart health. Please talk to your provider, visit 4myheart.com or call 1-800-432-7889 opt 2 to learn more.

Medical Information For Healthcare Providers: If you have questions about any of the tests in our Cardio IQ offering, please call Client Services at our Quest Diagnostics-Cleveland HeartLab Cardiometabolic Center of Excellence. They can be reached at 866.358.9828, option 1 to arrange a consult with our clinical education team.



Patient Information	Specimen Information	Client Information

## PATIENT PROGRESS SUMMARY

Test Name	01/26/2022 (Current)		03/12/2021	02/28/2021	10/27/2020
LIPID PANEL					
TRIGLYCERIDES	63	54	52	54	64
CHOLESTEROL, TOTAL	329	222	269	283	262
HDL CHOLESTEROL	58	52	55	59	47
LDL-CHOLESTEROL	255	155	200	208	199
CHOL/HDLC RATIO	5.7	4.3	4.9	4.8	5.6
NON-HDL CHOLESTEROL	271	170	214	224	215
LIPOPROTEIN FRACTIONATION, ION	MOE		·		
LDL PARTICLE NUMBER	2255	1110	1837	1962	1698
LDL SMALL	293	99	181	153	173
LDL MEDIUM	638	240	447	403	461
HDL LARGE	6150	4294	5806	6071	4218
APOLIPOPROTEINS					
LIPOPROTEIN (a)	10	12	<10	<10	12
APOLIPOPROTEIN B	161	104	121	138	135
LIPOPROTEIN FRACTIONATION, ION	MOE				
LDL PEAK SIZE	220.5	223.0	221.1	224.2	219.9
LDL PATTERN	A	Α	A	A	A



Patient Information	Specimen Information	Client Information

		ence Range/Com		
Analyte Name	In Range	Out Range	Reference Range	Lab
APOLIPOPROTEIN B		162	<90 mg/dL	Z4M
			sk category cut points (optimal, moderate, high) are er PS et al. Endocr Pract. 2017;23(Suppl 2):1-87.	based on National Lip
CHOL/HDLC RATIO		5.7	<3.6 calc	Z4M
CHOLESTEROL, TOTAL		327	<200 mg/dL	Z4M
HDL LARGE		6150	>6729 nmol/L	Z4M
Relative Risk: Optimal >6729; Moderate 67	29-5353; High <5353. Referenc	e Range: >6729 nm	ol/L.	1
LDL MEDIUM		637	<215 nmol/L	Z4M
Relative Risk: Optimal <215; Moderate 215	-301; High >301. Reference Ra	nge: <215 nmol/L.		
LDL PARTICLE NUMBER		2255	<1138 nmol/L	Z4M
Relative Risk: Optimal <1138; Moderate 113	38-1409; High >1409. Referenc	e Range: <1138 nm	ol/L.	
LDL PEAK SIZE		220.5	>222.9 Angstrom	Z4M
determined by The Cleveland HeartLab, Inc	. It has not been cleared or app	proved by the U.S. FI	method. This test was developed and its performan DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded	ical Laboratory
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL	b. It has not been cleared or applied to perform high-complexity to be a second sec	proved by the U.S. FI testing. This test is u 293		ical Laboratory
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL	b. It has not been cleared or applied to perform high-complexity to be a second sec	proved by the U.S. FI testing. This test is u 293	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L	ical Laboratory as investigational or fo
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142 LDL-CHOLESTEROL	c. It has not been cleared or app ied to perform high-complexity to -219; High >219. Reference Ra	proved by the U.S. FI testing. This test is u 293 nge: <142 nmol/L. 256	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc)	as investigational or fo
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142 LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre indicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing fo Lipid Association Recommendations for Pal using the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu	2. It has not been cleared or app ied to perform high-complexity to -219; High >219. Reference Ra evention; <70 mg/dL for patients Clinical assessment and meas or familial hypercholesterolemia tient-Centered Management of is a validated novel method pro-	293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest O Dyslipidemia: Part 1 oviding better accura	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L	Z4M Z4M >=190 mg/dL may atives of patients with a bobson T, et al. Nationa DL-C is now calculated
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142: LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre indicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing for Lipid Association Recommendations for Pat using the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL	2. It has not been cleared or appried to perform high-complexity to 2-219; High >219. Reference Ra 2-219; High >219. Referen	293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest C Dyslipidemia: Part 1 oviding better accura aq/FAQ164) 271	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree rela enomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of	Z4M Z4M >=190 mg/dL may atives of patients with a cobson T, et al. Nationa DL-C is now calculated f LDL-C. Martin SS et a Z4M
determined by The Cleveland HeartLab, Inc mprovement Amendments (CLIA) as qualif research. _DL SMALL Relative Risk: Optimal <142; Moderate 1424 _DL-CHOLESTEROL Desirable range <100 mg/dL for primary pre- ndicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing fi- h diagnosis. For questions about testing fi- lipid Association Recommendations for Pat- using the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL Non-HDL level >=220 is very high and may considered for all first-degree relatives of pat-	2. It has not been cleared or appried to perform high-complexity to 2-219; High >219. Reference Ra 2-219; High >219. Referen	293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest C Dyslipidemia: Part 1 oviding better accura aq/FAQ164) 271	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree rela Senomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of <130 mg/dL (calc)	Z4M Z4M >=190 mg/dL may atives of patients with a cobson T, et al. Nationa f LDL-C. Martin SS et a Z4M
determined by The Cleveland HeartLab, Inc mprovement Amendments (CLIA) as qualif esearch. LDL SMALL Relative Risk: Optimal <142; Moderate 142: LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre- ndicate familial hypercholesterolemia (FH). TH diagnosis. For questions about testing for Lipid Association Recommendations for Pail using the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL Non-HDL level >=220 is very high and may considered for all first-degree relatives of pail HDL CHOLESTEROL	2. It has not been cleared or appried to perform high-complexity to -219; High >219. Reference Ra evention; <70 mg/dL for patients Clinical assessment and meas or familial hypercholesterolemia tient-Centered Management of is a validated novel method pro ication.QuestDiagnostics.com/fa indicate genetic familial hyperca tients with an FH diagnosis.	293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest C Dyslipidemia: Part 1 oviding better accura aq/FAQ164) 271	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree relac Senomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of <130 mg/dL (calc) Clinical assessment and measurement of blood lipi	Z4M Z4M >=190 mg/dL may atives of patients with a cobson T, et al. Nationa DL-C is now calculated f LDL-C. Martin SS et a Z4M id levels should be
determined by The Cleveland HeartLab, Inc mprovement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142- LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre ndicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing fo Lipid Association Recommendations for Pat Jsing the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL Non-HDL level >=220 is very high and may considered for all first-degree relatives of pat HDL CHOLESTEROL LDL PATTERN	2. It has not been cleared or applied to perform high-complexity to -219; High >219. Reference Razevention; <70 mg/dL for patients. Clinical assessment and meas for familial hypercholesterolemiatient-Centered Management of is a validated novel method process. Com/fatients with an FH diagnosis. 58	broved by the U.S. FI testing. This test is u 293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest C Dyslipidemia: Part 1 byslipidemia: Par	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree rela enomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of <130 mg/dL (calc) Clinical assessment and measurement of blood lipi >39 mg/dL	Alignment Z4M   Z4M Z4M   >=190 mg/dL may Alignment   atives of patients with a sobson T, et al. National DL-C is now calculated f LDL-C. Martin SS et a sobstance   Z4M Z4M   id levels should be Z4M
determined by The Cleveland HeartLab, Inc mprovement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142- LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre ndicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing fo Lipid Association Recommendations for Pat Jama 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL Non-HDL level >=220 is very high and may considered for all first-degree relatives of pat HDL CHOLESTEROL LDL PATTERN Relative Risk: Optimal Pattern A; High Patter	2. It has not been cleared or applied to perform high-complexity to -219; High >219. Reference Razevention; <70 mg/dL for patients Clinical assessment and meas for familial hypercholesterolemia tient-Centered Management of is a validated novel method procession.QuestDiagnostics.com/fatients with an FH diagnosis.	broved by the U.S. FI testing. This test is u 293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest C Dyslipidemia: Part 1 byslipidemia: Par	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree rela enomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of <130 mg/dL (calc) Clinical assessment and measurement of blood lipi >39 mg/dL	Align of the second
determined by The Cleveland HeartLab, Inc Improvement Amendments (CLIA) as qualif research. LDL SMALL Relative Risk: Optimal <142; Moderate 142- LDL-CHOLESTEROL Desirable range <100 mg/dL for primary pre indicate familial hypercholesterolemia (FH). FH diagnosis. For questions about testing fo Lipid Association Recommendations for Pat using the Martin-Hopkins calculation, which JAMA. 2013;310(19): 2061-2068 (http://edu NON HDL CHOLESTEROL Non-HDL level >=220 is very high and may considered for all first-degree relatives of pat HDL CHOLESTEROL LDL PATTERN Relative Risk: Optimal Pattern A; High Patter LIPOPROTEIN (a)	2. It has not been cleared or appried to perform high-complexity to 219; High >219. Reference Rates a contract of the second sec	293 nge: <142 nmol/L. 256 s with CHD or diabeti urement of blood lipi a, please call Quest O Dyslipidemia: Part 1 boviding better accura aq/FAQ164) 271 holesterolemia (FH).	DA. The Cleveland HeartLab is regulated under Clin sed for clinical purposes. It should not be regarded <142 nmol/L <100 mg/dL (calc) c patients with >= 2 CHD risk factors. LDL-C levels d levels should be considered for all first degree rela Genomics Client Services at 1.866.GENE.INFO. Jac Journal of Clinical Lipidology 2015;9(2),129-169. LD cy than the Friedewald equation in the estimation of <130 mg/dL (calc) Clinical assessment and measurement of blood lipi >39 mg/dL A Pattern	A constraints and the second s

## **PERFORMING SITE:**

Z4M CLEVELAND HEARTLAB INC, 6701 CARNEGIE AVENUE SUITE 500, CLEVELAND, OH 44103-4623 Laboratory Director: BILL G RICHENDOLLAR, MD, CLIA: 36D1032987